Lobe Sciences Ltd.

Recent News

  • Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA

    Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA so that trained physicians may prescribe the psychedelics for patients across the country.Philip J. Young, Chairman and Chief Executive Officer of the...

    2023-02-06 8:00 AM EST
  • Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

    Vancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease, today announced that it has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS, Founder and Medical Director of Integrative Headache Medicine of New York, to study the tolerability and efficacy of our proprietary psilocin compound L-130, in patients...

    2023-01-26 8:30 AM EST
  • Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees

    Endorsement underscores transition into a fully integrated biotechnology companyVancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive shares in Lobe in lieu of the traditional cash renumeration. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "This is a...

    2023-01-23 9:00 AM EST
  • Lobe Sciences Provides Update For 2023 Milestones

    Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient focused psychedelic derived medicines for neurologic and brain disease today announced an updated overview for 2023.Mr. Philip Young, Chairman and Chief Executive Officer of the Company, stated, "2022 was a productive year for Lobe Sciences. We increased our intellectual property portfolio with several new chemical entities (NCEs) derived...

    2023-01-18 7:00 AM EST
  • Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

    Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130.Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "Subsequent to our last communication on the cGMP production of L-130, I wanted to update...

    2022-11-30 9:12 AM EST
  • Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022

    Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Executive Director, will present at the MONEYSHOW VIRTUAL EXPO, November 10th at 10:40AM EDT.The presentation will be available on demand through the MONEYSHOW VIRTUAL EXPO Meeting site at this link, Lobe Sciences is Developing Psychedelic Derived Medicines for Neurologic and Brain Disease.Registration for the event is accessible via the following link Free...

    2022-11-08 9:20 AM EST
  • Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials

    Vancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has completed the synthesis of bulk L-130, a proprietary form of psilocin, and of the clinical supplies to be used in upcoming trials. The L-130 was manufactured in compliance with U.S. cGMPs (Current Good Manufacturing Practices). Philip J. Young,...

    2022-10-13 8:00 AM EDT
  • Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry....

    2022-10-05 9:08 AM EDT